Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.